Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
COMPEL
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
- NCT04765059 ↗
- Active, not recruiting
- AstraZeneca
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on COMPEL yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on COMPEL so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients With EGFRm, Locally Advanced or Metastatic NSCLC Who Have Progressed Extracranially Following First-Line Osimertinib Therapy (COMPEL)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin; Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
- Arms
- Treatment Arm A · Experimental
- Treatment Arm B · Placebo comparator
- Enrollment
- 98
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- AstraZeneca with Parexel
- Start
- Sep 12, 2021
- Primary completion
- Oct 28, 2024
- Results posted
- Yes
- Registry record
- NCT04765059 · updated Jul 7, 2026